Je n'ai pas vu cette étude dans celles sur la citrulline : http://www.medicinabiomolecular.com.br/ ... o-1934.pdf
1. Cardiovasc Drug Rev. 2006 Fall-Winter;24(3-4):275-90.
Therapeutic use of citrulline in cardiovascular disease.
Romero MJ(1), Platt DH, Caldwell RB, Caldwell RW.
Author information:
(1)Department of Pharmacology and Toxicology, Medical College of Georgia, Augusta
GA, USA.
L-citrulline is the natural precursor of L-arginine, substrate for nitric oxide
synthase (NOS) in the production of NO. Supplemental administration L-arginine
has been shown to be effective in improving NO production and cardiovascular
function in cardiovascular diseases associated with endothelial dysfunction, such
as hypertension, heart failure, atherosclerosis, diabetic vascular disease and
ischemia-reperfusion injury, but the beneficial actions do not endure with
chronic therapy. Substantial intestinal and hepatic metabolism of L-arginine to
ornithine and urea by arginase makes oral delivery very ineffective.
Additionally, all of these disease states as well as supplemental L-arginine
enhance arginase expression and activity, thus reducing the effectiveness of
L-arginine therapy. In contrast, L-citrulline is not metabolized in the intestine
or liver and does not induce tissue arginase, but rather inhibits its activity.
L-citrulline entering the kidney, vascular endothelium and other tissues can be
readily converted to L-arginine, thus raising plasma and tissue levels of
L-arginine and enhancing NO production. Supplemental L-citrulline has promise as
a therapeutic adjunct in disease states associated with L-arginine deficiencies.
DOI: 10.1111/j.1527-3466.2006.00275.x
PMID: 17214603 [Indexed for MEDLINE]
